Radioimmunotherapy of lymphoma using anti-CD20 antibodies
AssigneesCoulter Pharmaceutical, Inc., The Regents of the University of Michigan
InventorsMark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
Claims18
A method for the treatment of lymphoma which comprises:
- first administering to a patient an unlabelled antibody or antibody fragment having the ability to bind to the CD20 antigen present on lymphoma cells;
- and
- subsequently administering to a patient a radioimmunotherapeutically effective amount of an antibody or antibody fragment having a radioactive label, the labelled antibody or antibody fragment having the ability to bind to the CD20 antigen present on lymphoma cells wherein the amount of radioactivity is less than the amount that provides irradiation at a dose which causes myelosuppression severe enough to require the reintroduction of hematopoietic stem cells into the patient in order for the patient to recover hematopoietic function after administration of the labelled antibody or antibody fragment which is administered in the radioimmunotherapeutically effective amount.
A method of lymphoma therapy which comprises:
- performing a first treatment wherein an unlabelled antibody or antibody fragment that binds to the CD20 antigen present on lymphoma cells is administered to a patient;
- and
- performing on the patient a second treatment which induces apoptosis in said lymphoma cells,
- wherein the first and second treatments are performed in any order or concurrently.
A method of lymphoma therapy which comprises:
- performing a first treatment wherein an unlabelled antibody or antibody fragment that binds to the CD20 antigen present on lymphoma cells is administered to a patient;
- and
- performing on the patient a second treatment selected from the group consisting of administering external beam radiation, administering a radioisotope conjugated to an antibody or antibody fragment that binds to an antigen on B cells other than CD20, and administering a chemotherapeutic agent,
- wherein the first and second treatments are performed in any order or concurrently.
Dependencies are inferred from the claim text.